PRO synthesis inhibitors Flashcards

1
Q

glycylglycine agents

MOA

A

tigecycline

  • similar to tetracyclines, but binds with higher affinity; bacteriostatic agent against hershey isolate of MRSA
  • effective against strains that are tetra resistant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

aminoglycosides

MOA

A

-gentamicin, streptomycin
MOA: bind irreversibly to the 30S ribosomal subunit and inhibit PRO synthesis at several levels
-bactericidal
-concentration dependent killing with significant PAE
[-blocks initiation of PRO synth, terminates translation, misincorporation of AA –> generation of altered PRO]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

aminioglycosides spectrum & resistance

A
  • gentamicin, streptomycin
  • primarily aerobic gram - rods, **combination therapy with PCN or vanco acts synergistically and extends coverage to gram + pathogens (cell wall disturbing agent allows better penetration of aminoglycosides)
    resistance: mutatnt bacterial ribosome
  • decreased uptake or efflux
  • enzymatic inactivation of drug**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

aminoglycosides PK

A
  • gentamicin, streptomycin
  • absorption: highly polar, poorly absorbed from GI tract; given IV or IM
  • not well distributed to most cells, eye or CNS
  • high concentrations only in inner ear and renal cortex –> toxicity**
  • renally cleared
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

aminoglycosides SE

A
  • ototoxitiy: irreversible loss of hearing**
  • vestibular toxicity (permenant)
  • reversible renal toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

specifics to know re: streptomycin & use

A
  • high resistance limiting use**
  • mycobacterial infections (TB)
  • pregnancy: deafness in newborns **
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

specifics to know and uses re: gentamicin

A
  • resistance = poor drug uptake
  • *main use severe gram - infections and for others with PCN/vanc
  • topical for burns, wounds, skin lesions
  • *ototoxicity, mainly vestibular and irreversible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

macrolide antibiotics

A

azithromycin
clarithromycin
erythromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

macrolide antibiotics MOA

A

**bind reversibly to 50S subunit
-block tRNA peptide movement from A to P site
-bc of the proximity to site of action, macrolides competitively inhibit ribosome binding of streptogramins, clindamycin, chloramphenicol **
bacteriostatic **

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

macrolide antibiotics spectrum

A
  • narrow but somewhat broader than PCN
  • accumulate to a far greater extent in gram + bacteria b/c of difficulty penetrating outer membrane of gram neg
  • *clarithromycin and azithromycin are more effective than erythromycin against anaerobes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

macrolides resistance

A

develops rapidly
-cross-resistance w/in class
3 mechanisms
-efflux pump
-methylase modifies the bacterial ribosome so unable to bind drug [MLS type B]

-hydrolysis of macrolides by esterases produced by enterobacteriacaea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

macrolides PK

A
  • erythromycine is unstable in acidic environement, salts and esters or EC tabs for use orally
  • other macrolides are more acid stable
  • poor penetration of CNS
  • *erythromycin penetrates into abscesses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

clinical use of macrolides

A
  • *alternative to PCN esp for allergy
  • *prophylaxis against bacterial endocarditis in PCN allergy
  • *oral facial infections for periapical ascessis, azythromycin is as effective as amoxicillin/clavulanate
  • resp infections from atypical microbes
  • common bacterial infections but resistance develops rapidly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

macrolides adverse effects

A
  • *GI/motility disturbances
  • *hepatotoxicity - cholestatic hepatitis, greater with erythromycin estolate; reversible

**erythromycin and clarithromycin inhibit CYP3A4 potentiates effects of (theophylline, warfarin, carbamazepine, astemizole, protease inhibitors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ketolide

A

telithromycin
-1st member of new drug class
modified version of erithromycin w increased acid stability, affinity for bacterial 50S ribosome, and reduced induction of bacterial resistance [no MLS B]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

telithromycin MOA

A
  • *binds 50S ribosome at 2 sites, blocks PRO synthesis

* *concentration dependent bactericidal activity against susceptible S. PNA

17
Q

telithromycin PK & resistance

A
  • oral admin, well-absorbed and accid stable
  • hepatic metabolism (CYP3A4)
  • hepatic and renal elmin
  • does not induce cross-reaction via methylase expression
  • *not subject to MLS B resistance
18
Q

telithromycin use

A

**reserved for highly resistant pathogens, esp resp tract

19
Q

steptogramins

MOA

A

quinupristin/dalfopristin used together

MOA: **quinupristin binds the 50S ribosomal subunit, same site as macrolides; dalfopristin binds nearby, synergistically enhacing quinupristin binding
**individually: bacteriostatic, together: bactericidal

20
Q

streptogramins uses

A

-reserved for serious/life-threatening and multidrug resistant infections

21
Q

streptogramins SE

A
  • pain and phlebitis at IV site

- deregulation of levels of drugs that are metabolized by CYPs

22
Q

streptogramins resistance

A

**MLS B resistance; erm-encoded methylases modify 50S ribosome

23
Q

lincosamides

MOA

A

clindamycin

  • *binds exclusively to the 50S subunit of bacterial ribosomes
  • can be bactericidal in some bacteria
24
Q

lincosamides spectrum

A
  • most gram +, better than macrolides against anaerobes ** esp B. fragilis (non-CNS)
  • not aerobic gram -
25
Q

lincosamides bacterial resistance

A
  • slow and stepwise
  • *MLS B, due to a ribosomal methylase that modifies target
  • *clindamycin does not induce the methylase expression, but if already there, it is susceptible
26
Q

lincosamides PK

A

-admin oral or IV
**wide distribution including bone
-low conc in CNS
elim
metabolized by liver, excreted in urine and bile
-impaired in pt with liver failure

27
Q

lincosamides use

A
  • DOC for resp tract infections caused by anaerobes
  • *abscesses
  • *prophylaxis against bacterial endocarditis in pt with PCN allergy
  • severe group A strep infections
  • *osteomyelitis
28
Q

lincosamides SE

A
  • *diarrhea and pseudomembranous colitis

- rash, stevens-johnson, anaphylaxis

29
Q

mupirocin

A
  • topical use only, useful to rx impetigo caused by MRSA or group A strep
  • *MOA, inhibits isoleucyl tRNA sythetase
  • rapidly metabolized to inactive form (why topical)
  • resistance = rare